Skip to main content

Khaitan & Co  and Cyril Amarchand Mangaldas are advising Indian drugmaker Gland Pharma on its planned $780 million IPO, with Herbert Smith Freehills and S&R Associates acting for the bookrunners and lead managers.

The Hyderabad-headquartered Gland Pharma, a subsidiary of China’s Fosun Pharmaceutical, is a major supplier of API heparin to hospitals in India. Its IPO will make it the first Indian company with a Chinese parent to list its equity shares on an Indian stock exchange.

The bookrunning lead managers are Kotak Mahindra Capital, Citigroup Global Markets India, Haitong Securities India and Nomura India.

The Khaitan team is being led by partners Abhimanyu Bhattacharya, Aditya Cheriyan, Niren Patel and Vivek Sriram.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Khaitan, SAM, Sidley advise on Torrent Power’s $413 mln QIP

by Nimitt Dixit |

Indian law firm Khaitan & Co has advised Torrent Power on its equity offering of $413 million through a qualified institutional placement of shares. Shardul Amarchand Mangaldas & Co and Sidley Austin advised the bookrunning lead managers on the deal.

Deals

IndusLaw guides Zepto’s $350 mln funding round

by Nimitt Dixit |

IndusLaw has guided Indian quick commerce company Zepto on its latest $350 million funding round led by Motilal Oswal's Private Wealth division.

Deals

9 firms advise on milestone $8.2 bln cross-border insurance deal

by Sarah Wong |

Global law firms Debevoise & Plimpton, Kirkland & Ellis and Herbert Smith Freehills are acting for Bermuda-based insurer Resolution Life on its $8.2 billion sale to Japan’s Nippon Life Insurance, the largest overseas acquisition by a Japanese insurer to date.